List view / Grid view
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead’s investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine’s U.S. regulatory approval.
27 June 2014 | By Gilead
If approved, sofosbuvir would be the first all-oral treatment regimen for patients in Japan with genotype 2 HCV...
26 June 2014 | By Janssen Pharmaceutica
New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide...
19 May 2014 | By Janssen Pharmaceutical Companies
Janssen-Cilag International NV today announced that its next generation protease inhibitor OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission for the treatment of adults with genotype 1 and 4 chronic hepatitis C...
25 September 2013 | By GSK
European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection...
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
18 April 2012 | By Gilead Sciences
Presentations include first results for lead hepatitis C candidate GS-7977 in treatment-naïve genotype 1 patients...
18 February 2012 | By Bristol-Myers Squibb
Three new grants awarded...
Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott’s ARCHITECT® system. Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus…
5 November 2011 | By
New long-term data show no development of resistance...
5 September 2011 | By Gilead Sciences, Inc.
Change does not affect ongoing "All Oral" clinical trials evaluating multiple direct-acting antivirals in combination...
